Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.71 |
| ▸ | CNR1 | P21554 | 10/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.69 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | PDE9A | O76083 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | LDHA | P00338 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23602301 | 1.00 | CNR2 (0.71) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL17084877 | 1.00 | CNR2 (0.71) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL17414504 | 0.99 | CNR2 (0.70) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL24541324 | 0.91 | CNR2 (0.68) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL23602308 | 0.90 | CNR2 (0.67) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL25213577 | 0.89 | CNR2 (0.55) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL17105786 | 0.87 | DRD3 (0.62) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL30631337 | 0.87 | DRD3 (0.62) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL23602381 | 0.87 | DRD3 (0.62) | CNR2CNR1OPRM1TRPV1GPR55 | |
| SCHEMBL17105752 | 0.87 | DRD3 (0.62) | CNR2CNR1OPRM1TRPV1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028059-B1 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | CARDIOL THERAPEUTICS INC (CA) | 2025-12-24 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023193244-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | 北京睿创康泰医药研究院有限公司 | 2023-10-12 | — | — | WO | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220347118-A1 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | CARDIOL THERAPEUTICS INC. (CA) | 2022-11-03 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-4028059-A1 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | Cardiol Therapeutics Inc. (CA) | 2022-07-20 | — | — | EP | claimed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630492-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2026-05-19 | — | — | US | disclosed |
| US-20260125454-A1 | ANTI-CGRP ANTIBODY AND USE | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4725478-A2 | RAPIDLY INFUSING PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS | Orcosa Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20190084909-A1 | FLUORINATED CBD COMPOUNDS, COMPOSITIONS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM (IL) | 2019-03-21 | — | — | US | disclosed |
| US-8119697-B2 | Anti-nausea and anti-vomiting activity of cannabidiol compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-02-21 | — | — | US | disclosed |
| US-8119697-B2 | Anti-nausea and anti-vomiting activity of cannabidiol compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-02-21 | — | — | US | disclosed |
| US-20070049645-A1 | Anti-nausea and anti-vomiting activity of cannabidiol compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-03-01 | — | — | US | disclosed |
| US-20070049645-A1 | Anti-nausea and anti-vomiting activity of cannabidiol compounds | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347118-A1 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | TTPA, CPT2, ECH1 | CNR2 15/4885CNR1 27/4885OPRM1 661/4885 |
| US-12630492-B2 | Cannabinoid derivatives | CNR2, CNR1, OPRM1 | CNR2 1/4885CNR1 2/4885OPRM1 3/4885 |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CNR2 834/4885CNR1 382/4885OPRM1 458/4885 |
| US-20190084909-A1 | FLUORINATED CBD COMPOUNDS, COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FXR1 | CNR2 1/4885CNR1 2/4885OPRM1 274/4885 |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR2 3/4885CNR1 1/4885OPRM1 24/4885 |
| US-20260125454-A1 | ANTI-CGRP ANTIBODY AND USE | NPY1R, NPY2R, NPY5R | CNR2 705/4885CNR1 553/4885OPRM1 220/4885 |
| US-20070049645-A1 | Anti-nausea and anti-vomiting activity of cannabidiol compounds | FAAH, HRH1, HRH3 | CNR2 7/4885CNR1 12/4885OPRM1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.